Drug Trial Radar · NCT07896915
A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
32
Actual
Start
Aug 3, 2026
Primary completion
Dec 25, 2026
Study completion Dec 25, 2026
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, open-label, randomized, four-period dosing clinical study designed to evaluate the pharmacokinetic characteristics of HS-20118 under different dosing conditions in healthy participants. It is planned to enroll 32 healthy participants.
Conditions
- Healthy Participants
Interventions
HS-20118Drug
HS-20118 tablets will be administered orally as a single dose of 400 mg (two 200 mg tablets) with approximately 180 mL of water in each of the 4 treatment periods, separated by a washout period of at least 42 days. In each period, the drug will be administered under specific dietary and fasting conditions.
HS-20118Drug
HS-20118 tablets will be administered orally as a single dose of 400 mg (two 200 mg tablets) with approximately 180 mL of water in each of the 4 treatment periods, separated by a washout period of at least 42 days. In each period, the drug will be administered under specific dietary and fasting conditions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of HS-20118 under different administration conditionsTime frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
- Tmax of HS-20118 under different administration conditionsTime frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
- AUC0-t of HS-20118 under different administration conditionsTime frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
- AUC0-inf of HS-20118 under different administration conditionsTime frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
- t1/2 of HS-20118 under different administration conditionsTime frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
- CL/F of HS-20118 under different administration conditionsTime frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
- Vd/F of HS-20118 under different administration conditionsTime frame: Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Haikou People's Hospital
Haikou, Hainan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.